State Attorneys General pursue consumer protection law claims against stem cell clinics

If you’ve ever seen an ad that promises “Life Without Pain!” (usually in a font that screams “trust me, I’m science”),
you’ve already met the modern stem cell marketplace. It’s a weird little ecosystem where legitimate regenerative
medicine research shares a zip code with high-pressure dinner seminars, “patient-funded trials,” and
“miracle” claims that sound like they were written by a superhero origin-story generator.

Increasingly, state Attorneys General (AGs) are stepping in with a practical legal toolset: consumer protection laws.
These cases don’t require an AG to become a biomedical peer reviewer overnight. Instead, they focus on a simpler
question: were consumers deceivedespecially about safety, efficacy, approval status, and what the treatment can
realistically do?

Why state AGs are jumping into the stem cell clinic fight

Stem cells are real. Their medical potential is real. But the “direct-to-consumer stem cell clinic” industry has
repeatedly sold hope with a side of hypeoften for thousands (or tens of thousands) of dollars out of pocket.
Federal agencies like the FDA and FTC do bring cases, but state AGs are uniquely positioned to move fast, target
local harm, and use state laws designed to stop deceptive sales practices.

And deceptive health marketing isn’t a victimless crime. The FDA has warned that many regenerative medicine
products are illegally marketed as safe and effective for a wide range of conditions without adequate study, and it
has highlighted serious risks reported in connection with unapproved productsranging from infections to tumor
formation and more. When the product is injected into someone’s body, “misleading” can become “medical disaster”
in a hurry.

What “consumer protection law claims” actually mean

Consumer protection statutes (often called “UDAP” lawsUnfair and Deceptive Acts and Practices) are the legal
equivalent of a sturdy multi-tool. AGs can use them to challenge:

• Unsubstantiated efficacy claims (“treats Parkinson’s,” “reverses COPD,” “fixes lupus,” etc.).
• False statements about approval or legality (implying the therapy is FDA-approved when it isn’t).
• Misleading “clinical trial” language (especially when patients pay large sums to participate).
• Deceptive testimonials and before/after narratives that imply typical results.
• Omissions (downplaying known risks, complications, or the experimental nature of the product).

The remedies are often very consumer-focused: injunctions to stop the marketing, restitution or refunds, civil
penalties, and sometimes bans on future marketing of regenerative medicine services. In other words: “Stop saying
that, stop selling that, and pay people back.”

The enforcement playbook: how these cases tend to unfold

1) The marketing sets off alarms

Many cases begin the same way: flashy ads, seminars, mailers, “free dinner” events, or “educational” sessions that
look suspiciously like sales funnels with a side of chicken parmesan. Investigators may see sweeping claims
(treating multiple serious diseases), “limited-time” discounts, or an unusual emphasis on elderly or disabled
consumers.

2) The science doesn’t match the sales pitch

AG complaints frequently argue that claims lacked “competent and reliable scientific evidence” or adequate
substantiation. The gap between “promising research exists” and “this clinic can treat your ALS next Tuesday” is
where consumer protection law lives.

3) The case targets deception, not innovation

A key theme: states aren’t trying to ban regenerative medicine research. They’re targeting marketing that presents
experimental interventions as proven curesor implies official endorsement that doesn’t exist.

Real case examples: the states are not just talking about it

New York: a $5.1 million judgment over “magical” claims

New York’s Attorney General secured a $5.1 million judgment against a now-defunct New York City clinic and its
managing doctor over allegations of fraudulent and illegal advertising of stem cell procedures. The AG’s office
described broad marketing claims that the clinic could treat a long list of serious conditions using patients’ own
stem cellsand emphasized that there was no adequate scientific substantiation for those sweeping promises.
The court also permanently enjoined deceptive marketing practices in the case.

Washington: “patient-funded research” that looks like pay-to-play medicine

Washington’s Attorney General filed a lawsuit alleging a Seattle-based business deceptively marketed stem cell
injections as treatments for COVID-19 and numerous serious conditions. The complaint highlighted that people were
charged substantial out-of-pocket sums for purported “patient funded research,” while the “trials” allegedly did
not follow generally accepted standards and involved conflicts of interest. The lawsuit sought restitution and
penalties under the state’s Consumer Protection Actclassic consumer-protection framing: if it walks like a sales
pitch and quacks like snake oil, call it what it is.

Nebraska (and coordination with Iowa): claims, seminars, and millions in sales

Nebraska’s Attorney General sued an Omaha-area clinic and related entities, alleging deceptive and misleading
claims about the ability of stem cell therapy to treat specific conditions (including joint pain and COPD), plus
misrepresentations about safety and dosage. The AG’s office described aggressive marketing through local media and
in-person seminars and alleged the defendants made over $2 million from the practices at issue. Notably, the press
release also referenced FDA warnings about unapproved stem cell treatments and safety concernsshowing how state
consumer protection and federal regulatory context can reinforce each other.

Georgia + FTC: a joint enforcement model with big financial consequences

Georgia’s Attorney General partnered with the Federal Trade Commission in litigation involving the Stem Cell
Institute of America and related defendants. The FTC described a court outcome that included bans on marketing
regenerative medicine treatments and orders totaling more than $5.1 million in refunds and civil penalties tied to
Georgia’s state-law claims. The case also described a broader “clinic training” modelteaching providers how to
market unproven interventions and recruit patients through advertising and seminars. This matters because it shows
states aren’t only chasing individual storefront clinics; they can also pursue the marketing infrastructure behind
them.

North Dakota: refunds and a halt to noncompliant injections

North Dakota’s consumer protection action involving a Bismarck clinic ended with an agreement that included
consumer refunds and a requirement to discontinue certain stem cell injections not approved by the FDA. It’s a
smaller-dollar case than some headline-grabbers, but it’s a useful example of what states can do early: act on
complaints, demand refunds, and stop questionable practices before they become a bigger local industry.

Arkansas: claims tied to COVID-19 and “umbilical cord stem cell infusions”

In Arkansas, a consumer protection complaint described allegations that a health center exploited COVID-19 fears
and made false or misleading statements to consumers. The filing described marketing related to COVID-19 services,
including statements on the business’s website discussing intravenous infusion of mesenchymal stem cells and
umbilical cord stem cell infusions as a treatment for COVID-19, along with requests for restitution and civil
penalties under the state’s deceptive trade practices law.

Where the FDA fits in: the line between “medicine” and “marketed miracle”

State AG cases often echo the FDA’s core message: most regenerative medicine products marketed for conditions like
chronic pain, neurological disorders, cardiovascular disease, orthopedic injuries, and COVID-related uses are not
approved and may be illegally marketed. The FDA has also warned that unapproved productssometimes described as
“stem cells,” “exosomes,” or related termscan pose serious safety risks.

This doesn’t mean all stem cell uses are illegitimate. It does mean that when a clinic presents experimental
interventions as established treatments, the advertising can collide with both federal regulatory standards and
state consumer-protection rules. And states don’t need to prove a therapy is “bad science” in the abstract; they
can argue it was sold with deceptive claims that a reasonable consumer would rely on when making health decisions.

Common red flags consumers (and investigators) keep seeing

• “Treats everything” menus (from arthritis to Alzheimer’s to asthma to autoimmune disease).
• Pay-to-participate “clinical trials” that look like sales programs with lab coats.
• Heavy reliance on testimonials instead of published clinical evidence.
• Seminars and mailers designed to generate urgency and emotion, not informed consent.
• Vague product descriptions (“stem cell soup,” “exosomes,” “birth tissue,” “secret sauce”).
• Approval fog (“FDA registered,” “compliant,” “exempt,” “same-day,” “minimal manipulation”)
  presented as if it means “FDA approved.”

What legitimate regenerative medicine usually looks like (spoiler: it’s less flashy)

Real innovation typically involves carefully designed clinical trials, independent oversight, transparent risks,
clear endpoints, and publication (even when results are disappointing). It rarely involves “limited-time offers,”
claims of treating dozens of unrelated conditions, or telling patients that paying $10,000 out of pocket is
“participating in research.”

A good rule of thumb: if you’re being charged substantial money because something is experimental, ask
why the financial risk is on the patient rather than on sponsors, institutions, or research funding mechanisms.
There are exceptions in medicine, but “you pay to be the experiment” is exactly the kind of structure that has
attracted AG scrutiny.

What this enforcement wave means for clinics and the broader market

For clinics: marketing is no longer a “wild west” side quest. State AGs canand increasingly dotreat medical
advertising like any other consumer product claim: if you can’t substantiate it, don’t sell it. Clinics that want
to operate responsibly may need tighter review of advertising, clearer disclosures, and a hard pivot away from
broad disease-treatment claims.

For consumers: these actions can change the incentive structure. When deceptive marketing becomes expensive
(refunds, penalties, bans, judgments), the “easy money” business model starts looking less easy. And that’s the
point: consumer protection law isn’t anti-science. It’s anti-fiction.

Conclusion

State Attorneys General are increasingly using consumer protection laws as a direct response to a marketplace
where hope is sometimes sold faster than evidence. The pattern is consistent: sweeping claims, vulnerable
consumers, big price tags, and thin scientific support. By focusing on deceptionrather than trying to referee the
entire field of regenerative medicineAGs can move quickly, seek refunds, stop misleading ads, and partner with
federal agencies when appropriate.

The bottom line: if a clinic’s marketing sounds like it could cure the human condition in three injections or less,
state consumer protection lawyers are starting to treat that the same way they’d treat a “miracle investment”
pitch. Because medically speaking, it kind of is.

Experiences from the front lines (a 500-word reality check)

Talk to people who work around these casespatient advocates, investigators, regulatory lawyers, even skeptical
cliniciansand you’ll hear the same set of experiences repeated with minor variations, like a traveling Broadway
show titled Hope, Hype, and a Credit Card Machine.

First, there’s the consumer experience. It often begins with chronic pain, a progressive diagnosis, or a loved one
who’s desperate for options. Then comes the invitation: a “free educational seminar” at a hotel conference room or
a dinner event where the speaker uses just enough scientific vocabulary to feel convincing (“mesenchymal,”
“exosomes,” “regenerative cascade”) and just enough storytelling to feel personal (“I’ve seen people walk again”).
People describe feeling a mix of excitement and relieffinally, something that sounds proactive. The emotional
weight matters, because it’s exactly what makes exaggerated claims so powerful.

Next, there’s the sales process wearing a lab coat. Consumers report “consultations” that feel more like a funnel:
a quick medical intake, then a confident recommendation, then the price. The number is often framed as an
investment in your future rather than a purchase of an unproven intervention. Some people remember being told that
insurance “doesn’t keep up with innovation,” which is a clever way of making a lack of coverage sound like a badge
of honor. And when “research” is mentioned, it’s sometimes paired with a payment requirementan arrangement that
can blur the ethical line between clinical care, experimentation, and marketing.

From the investigator’s side, the experience can be surprisingly old-fashioned: follow the advertising, document
the claims, compare them to evidence, and ask whether consumers are being misled. The “medical” wrapping paper
doesn’t change the consumer-protection question. Investigators describe spending real time on screenshots,
recorded presentations, fine-print disclaimers, and the gap between what a clinic promises publicly and what it
admits privately when challenged.

Providers who try to do things the right way describe a different frustration: the clinics that overpromise can
poison the well for everyone. Legitimate researchers and ethical clinicians end up spending time undoing
misinformationexplaining that “experimental” doesn’t mean “guaranteed,” that a clinical trial isn’t supposed to
look like a retail purchase, and that “stem cell” is not a magic word that makes risk disappear. They’ve seen
patients arrive after spending life savings, feeling embarrassed, and still in pain.

Finally, there’s the consumer aftertaste: confusion. People ask, “If it wasn’t proven, how was it allowed to be
advertised like that?” That question is a big reason state AGs matter here. When enforcement actions succeed, they
do more than punish a bad actorthey clarify the rules of the road. And for consumers navigating scary health
decisions, clarity is its own kind of medicine.